Abstract: Disclosed herein are methods of treating a disease or condition modulated by large-conductance potassium channels, the methods including administering, to a patient in need thereof, an effective amount of a large-conductance potassium channel modulating compound. Exemplary disease or conditions that may be treated include, without limitations, protection against ischemia and hypoxia at multiple points throughout the body, as well as respiration stimulation in the presence of such conditions (both local and systemic). Also described herein are pharmaceutical compositions for use in the methods of treatment of a disease or condition modulated by large-conductance potassium channels, and methods of preparing such pharmaceutical compositions.

Abstract: Disclosed in certain embodiments are methods of treating neurological ventilatory insufficiency comprising administering to patient in need thereof, an effective amount of a compound selected from Formula (I) as disclosed herein.

Abstract: Representative embodiments of the present invention provide for novel, minimally invasive implantable devices and methods for targeted tissue drug delivery of cardiovascular drugs.

Abstract: Disclosed in certain embodiments a nasal formulation comprising a compound of Formula (I) as disclosed herein and a pharmaceutically acceptable excipient.

Abstract: Disclosed in certain embodiments is a method for treating chronic pain with a hetero-substituted acetanilide compound that modulates the adenosine receptor. Disclosed in certain embodiments is a method for treating neuropathic pain (e.g., acute or chronic) with a hetero-substituted acetanilide compound that modulates the adenosine A3 receptor. Disclosed in certain embodiments is a method for treating inflammation (e.g., local inflammation or systemic inflammation), an inflammatory response, or an inflammatory condition with a hetero-substituted acetanilide compound.

Abstract: Disclosed in certain embodiments a parenteral formulation comprising a compound of Formula (I) as disclosed herein and a pharmaceutically acceptable excipient, wherein the formulation maintains at least 90% of the compound after accelerated storage conditions of 25° C. at 60% relative humidity for 2 weeks.

Abstract: Methods and compositions are provided for treating individuals exhibiting opioid withdrawal symptoms with opioid, benzodiazepine and other drugs of abuse by administering an opioid receptor antagonist agent together with a respiratory stimulant to reverse the effects of opioid withdrawal symptoms, including respiratory depression, sedation, and hypotension. Methods and compositions are also provided for treating stimulant overdose with a benzodiazepine and beta-adrenergic blocking agent. Methods and compositions are also provided for treating concurrent stimulant and opioid overdose comprising administering to a patient in need thereof a benzodiazepine and an opioid antagonist.

Abstract: Representative embodiments of the present invention provide for novel, minimally invasive implantable devices and methods for targeted tissue drug delivery of cardiovascular drugs.

Abstract: Disclosed in certain embodiments is a pharmaceutical composition for parenteral administration comprising: an aqueous solution comprising ketorolac or a pharmaceutically acceptable salt thereof in an amount from about 0.1 mg/mL to about 10 mg/mL; and a pharmaceutically acceptable excipient; wherein the formulation is substantially free of alcohol.

Abstract: Representative embodiments of the present invention provide for novel, minimally invasive implantable devices and methods for targeted tissue drug delivery of cardiovascular drugs.

Abstract: Disclosed in certain embodiments is a method for treating chronic pain with a hetero-substituted acetanilide compound that modulates the adenosine receptor. Disclosed in certain embodiments is a method for treating neuropathic pain (e.g., acute or chronic) with a hetero-substituted acetanilide compound that modulates the adenosine A3 receptor. Disclosed in certain embodiments is a method for treating inflammation (e.g., local inflammation or systemic inflammation), an inflammatory response, or an inflammatory condition with a hetero-substituted acetanilide compound.

Abstract: Disclosed in certain embodiments is a pharmaceutical composition for parenteral administration comprising: an aqueous solution comprising ketorolac or a pharmaceutically acceptable salt thereof in an amount from about 0.1 mg/mL to about 10 mg/mL; and a pharmaceutically acceptable excipient; wherein the formulation is substantially free of alcohol.

Abstract: Representative embodiments of the present invention provide for novel, minimally invasive implantable devices and methods for targeted tissue drug delivery of cardiovascular drugs.

Abstract: Representative embodiments of the present invention provide for novel, minimally invasive implantable devices and methods for targeted tissue drug delivery of cardiovascular drugs.

Abstract: Disclosed in certain embodiments is a pharmaceutical composition for parenteral administration comprising: an aqueous solution comprising ketorolac or a pharmaceutically acceptable salt thereof in an amount from about 0.1 mg/mL to about 10 mg/mL; and a pharmaceutically acceptable excipient; wherein the formulation is substantially free of alcohol.

Abstract: Disclosed in certain embodiments is a pharmaceutical composition for parenteral administration comprising: an aqueous solution comprising ketorolac or a pharmaceutically acceptable salt thereof in an amount from about 0.1 mg/mL to about 10 mg/mL; and a pharmaceutically acceptable excipient; wherein the formulation is substantially free of alcohol.

Abstract: Representative embodiments of the present invention provide for novel, minimally invasive implantable devices and methods for targeted tissue drug delivery of cardiovascular drugs.

Abstract: Representative embodiments of the present invention provide for novel, minimally invasive implantable devices and methods for targeted tissue drug delivery of cardiovascular drugs.

Abstract: Disclosed in certain embodiments is a pharmaceutical composition for parenteral administration comprising: an aqueous solution comprising ketorolac or a pharmaceutically acceptable salt thereof in an amount from about 0.1 mg/mL to about 10 mg/mL; and a pharmaceutically acceptable excipient; wherein the formulation is substantially free of alcohol.

Abstract: Disclosed in certain embodiments is a pharmaceutical composition for parenteral administration comprising: an aqueous solution comprising ketorolac or a pharmaceutically acceptable salt thereof in an amount from about 0.1 mg/mL to about 10 mg/mL; and a pharmaceutically acceptable excipient; wherein the formulation is substantially free of alcohol.